Swiss dental health startup vVardis had a rough introduction to public markets on the New York Stock Exchange. The company raised $175 million by selling 9.7 million shares at $18 each—below the $21–24 range it had marketed—and the stock still closed its first trading day down 22%, according to Reuters. The shares opened at $14, well below the offer price, and never recovered.
For investors, the message is clear: even a discounted IPO price wasn't enough to attract buyers. The "break"—when a stock falls below its offer price on day one—is a red flag that the company's valuation was out of step with what institutional investors were willing to pay.
What went wrong?
vVardis, founded in 2020 and based in Zug, Switzerland, is an early-stage company focused on dental health. It has yet to turn a profit and relies heavily on a single customer for revenue, according to analyst firm IPOX. Those two factors were sticking points during the roadshow, as investors grew more price-sensitive about loss-making startups.
IPO pricing is a delicate balancing act. Underwriters typically aim to set an offer price that gives the stock a small cushion on day one, so trading looks orderly and the deal becomes a positive reference point for future listings. When a company prices below its marketed range, it's often a sign that demand was weaker than expected. But vVardis didn't even get that cushion—opening at $14 and closing down 22% suggests that public-market buyers valued the company far below what the IPO price implied.
This is not an isolated event. The broader IPO market has been choppy, with investors increasingly demanding clearer paths to profitability and more diversified revenue streams. Recent tech IPOs have also split on debut, showing that selectivity is the new norm.
What it means for investors
For everyday investors, the takeaway is about valuation discipline. When a company like vVardis prices below range and still falls, it signals that the market is unwilling to pay premium prices for early-stage healthcare companies without proven profitability. This could reset expectations for other healthcare listings, giving investors more leverage to push for lower valuations, smaller deal sizes, or clearer supports like more transparent customer concentration and a tighter path to profitability.
Healthcare is often called a "defensive" sector because demand for treatment doesn't swing much with the economy. But that doesn't mean every healthcare IPO is a safe bet. Early-stage companies with concentrated revenue and ongoing losses carry significant risk, and the market is clearly factoring that in.
For those watching the Swiss market, vVardis's stumble is a reminder that even well-funded startups can face headwinds. Strong results from established companies like Richemont haven't always lifted the broader market, and now a high-profile IPO has disappointed. The pricing news had already hinted at trouble, and the first-day performance confirmed it.
Investors should watch how this affects upcoming healthcare IPOs. If more companies are forced to price below range or trim their deal sizes—as vVardis did when it trimmed its IPO to up to $200 million—it could be a sign that the market is becoming more rational about valuations. For now, the lesson is simple: a low IPO price doesn't guarantee a successful debut, and investors are more discerning than ever.
As always, this is not a recommendation to buy or sell any stock. It's a reminder to look beyond the headlines and understand the fundamentals—like revenue concentration and profitability—before investing in any early-stage company.
